Research and development expenses were USD 18.1 million for the quarter, against USD 22.5 million a year earlier. The decrease of USD 4.4 million was partly offset by an increase of USD 0.3 million in research and laboratory expenses. The filing attributes it mainly …
President and Chief Executive Officer David Somo said customer engagements expanded as the transition to higher-voltage DC architectures is acceleratingDemandfor solid-state circuit protection. He cited a prototype demonstrated with Power Integrations, shipments of new reference design kits and progress with Stellantis.
Management said overall revenue performance remains below its expectations, and cited the strength of its largest client relationships, the acceleration of contract bookings and continued improvement in operating efficiency.
The 10-Q attributes theRevenueincrease primarily to strong deployment growth in prior periods. The company's common stock trades on theNasdaqGlobal Select Market.
The company was incorporated in Delaware in August 2023 under the name EnCarda, Inc. It reported noRevenuefigure for the period.
Management said lower enrollment across its KinderCare centers continued to pressure revenue, partly offset by growth in Champions and contributions from small group enrichment and newer centers. Average weekly early childhood enrollments declined approximately 6% against the prior year, including a negative impact of …
The filing states that the company has incurred net losses in each reporting period since inception, including a net loss of USD 190.0 million for the nine months ended September 30, 2026. It reports an accumulated deficit of USD 1.7 billion and says it …
Chief executive Cory Miller said the quarter was defined by speed of execution since theMergerclosed in August. The company has identified approximately USD 30 million in annualized cost synergies and is working onRevenueopportunities across its brands. Gross profit of USD 437.7 million represented a …
The filing says the company acquired Event Risk, which operates as Knightscope Security Force, for total purchase consideration of approximately USD 18.0 million. Following the integration, its chief operating decision maker began reviewing consolidated operating results as a single operating unit rather than two …
The filing states that the company initiated the rolling BLA submission of miv-cel in stiff person syndrome in the second quarter of 2026 and completed it in the fourth quarter of 2026. It is seeking priority review under the Regenerative Medicine Advanced Therapy designation. …